Holen Sie sich die Stockscreener-App
0.72
7.78%
0.052
Schlusskurs vom Vortag:
$0.668
Offen:
$0.71
24-Stunden-Volumen:
41,905
Relative Volume:
0.18
Marktkapitalisierung:
$1.50M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-6.64M
KGV:
-0.0398
EPS:
-18.0702
Netto-Cashflow:
$-5.60M
1W Leistung:
+6.43%
1M Leistung:
-38.46%
6M Leistung:
-98.30%
1J Leistung:
-98.33%
1-Tages-Spanne:
$0.67
$0.72
1-Wochen-Bereich:
$0.602
$0.72
52-Wochen-Spanne:
$0.5949
$52.40
Clearmind Medicine Inc Stock (CMND) Company Profile
Firmenname
Clearmind Medicine Inc
Sektor
Branche
Telefon
-
Adresse
-
Compare CMND vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CMND
Clearmind Medicine Inc
|
0.72 | 1.40M | 0 | -6.64M | -5.60M | -18.07 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Clearmind Medicine Inc Aktie (CMND) Neueste Nachrichten
Market Overview: Is Clearmind Medicine Inc in a bullish channel2026 Big Picture & Real-Time Buy Signal Alerts - baoquankhu1.vn
[POS AM] Clearmind Medicine In... - Stock Titan
CMND SEC FilingsClearmind Medici 10-K, 10-Q, 8-K Forms - Stock Titan
Analyst Upgrade: Is Clearmind Medicine Inc a turnaround story2026 Catalysts & Free Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Form 6K Clearmind Medicine Inc For: 19 March - Investing.com
[6-K] Clearmind Medicine Inc. Cur... | CMND SEC FilingForm 6-K - Stock Titan
Clearmind Medicine Inc. Advances CMND-100 Clinical Trial for Alcohol Use Disorder with Successful Cohort Treatment - Quiver Quantitative
Clearmind Medicine Reports Successful Ongoing Treatment of Participants at US Sites in its FDA-approved CMND-100 Phase I/IIa Clinical Trial for Alcohol Use Disorder - weeklyvoice.com
No serious adverse events as Yale, Johns Hopkins test AUD drug - Stock Titan
Form 6K Clearmind Medicine Inc For: 19 March By Investing.com - Investing.com Canada
Clearmind Medicine regains compliance with NASDAQ minimum bid price rule - MSN
Clearmind Medicine secures six patents in Hong Kong By Investing.com - Investing.com South Africa
Aug Patterns: How do insiders feel about Clearmind Medicine Inc - baoquankhu1.vn
Clearmind Medicine secures six patents in Hong Kong - Investing.com
Clearmind Medicine Announces Publication of Six Innovative Patents in Hong Kong for Next-Generation Psychedelic-Based Combination Therapies - The Manila Times
Clearmind Medicine Inc. Announces Publication of Six Patents in Hong Kong for Novel Psychedelic Combination Therapies - Quiver Quantitative
Six new Hong Kong combo patents for Clearmind (Nasdaq: CMND) - Stock Titan
Six Clearmind psychedelic drug combos published as Hong Kong patents - Stock Titan
SciSparc’s NeuroThera-Backed Collaboration Spurs New Depression Therapy Patent Filing - TipRanks
SciSparc discloses patent application for depression yherapy - TipRanks
NeuroThera, Clearmind Advance Non-Hallucinogenic Depression Therapy With New Patent Filing - TipRanks
SciSparc: NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy - Bitget
NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy - TheNewswire
NeuroThera LabsClearmind Medicine Collaboration Leads to Patent Application for Depression Therapy - Yahoo Finance
Non-hallucinogenic depression combo MEAI-PEA seeks Hong Kong patent - Stock Titan
Clearmind advances enrollment in alcohol disorder drug trial By Investing.com - Investing.com Nigeria
Clearmind files patent for obesity, liver disease treatment combo - Investing.com Nigeria
Clearmind files Hong Kong patent for depression treatment combo - Investing.com India
Clearmind files Hong Kong patent for depression treatment combo By Investing.com - Investing.com Australia
Clearmind Medicine Inc. Announces Hong Kong Patent Filing for Depression Therapy - marketscreener.com
Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy - Bitget
Clearmind Medicine Inc. Files Patent for Innovative Non-Hallucinogenic Therapy Combining MEAI and PEA to Address Major Depressive Disorder - Quiver Quantitative
Clearmind Medicine (NASDAQ: CMND) files Hong Kong patent for MEAI-PEA depression therapy - Stock Titan
SciSparc: NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease - Bitget
SciSparc Ltd. Advances Collaboration with NeuroThera Labs Inc. and Clearmind Medicine Inc. for Novel Combination Therapy Targeting Obesity and MASLD. - Quiver Quantitative
SciSparc: NeuroThera Labs Announces Publication of - GlobeNewswire
Clearmind advances enrollment in alcohol disorder drug trial - Investing.com India
Clearmind Medicine Advances Recruitment for CMND-100 Trial's Third Cohort at Yale, Johns Hopkins and Tel Aviv Sites Following Recent Positive Topline Results - Bitget
NeuroThera and Clearmind Advance Patent for Obesity and Liver Disease Therapy - TipRanks
Clearmind Medicine Inc. Advances Enrollment for Third Cohort in Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder - Quiver Quantitative
Non-hallucinogenic AUD drug CMND-100 moves into third trial cohort - Stock Titan
NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease - TheNewswire
NeuroThera Labs Announces Publication of International Patent in Collaboration With Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease - Yahoo Finance
Clearmind files patent for obesity, liver disease treatment combo By Investing.com - Investing.com Canada
Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease - Bitget
Finanzdaten der Clearmind Medicine Inc-Aktie (CMND)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):